BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51:880-8. [PMID: 32237087 DOI: 10.1111/apt.15689] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
2 Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, Ferrante M, Aden K. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:282-91. [PMID: 35484689 DOI: 10.1111/apt.16955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
4 Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Aliment Pharmacol Ther 2022;55:1534-44. [PMID: 35246988 DOI: 10.1111/apt.16848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflamm Bowel Dis 2022:izac100. [PMID: 35590447 DOI: 10.1093/ibd/izac100] [Reference Citation Analysis]
6 Wang W, Pekow J. Editorial: response to tofacitinib is associated with high rates of long-term treatment persistence. Aliment Pharmacol Ther 2022;55:1222-3. [PMID: 35429025 DOI: 10.1111/apt.16891] [Reference Citation Analysis]
7 Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther 2022;55:1320-9. [PMID: 35218038 DOI: 10.1111/apt.16817] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02215-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, Ruan G, Bai X. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology 2022;105:108517. [DOI: 10.1016/j.intimp.2022.108517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hyun HK, Zhang H, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02225-w] [Reference Citation Analysis]
11 Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx LAAP, Jones GR, Lees CW. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211064004. [PMID: 34987608 DOI: 10.1177/17562848211064004] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Katsanos KH, Armuzzi A. Effectiveness and safety of tofacitinib in ulcerative colitis: Done is better than perfect. Dig Liver Dis 2021:S1590-8658(21)00857-4. [PMID: 34953762 DOI: 10.1016/j.dld.2021.11.017] [Reference Citation Analysis]
13 Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
14 Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D'Haens GR, Löwenberg M. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1288-97. [PMID: 33405424 DOI: 10.1097/MEG.0000000000002028] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sleutjes JAM, Roeters van Lennep JE, Boersma E, Menchen LA, Laudes M, Farkas K, Molnár T, Kennedy NA, Pierik MJ, van der Woude CJ, de Vries AC. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther 2021;54:999-1012. [PMID: 34453860 DOI: 10.1111/apt.16580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lo SW, Connell W, Kamm MA, Lust M, Wright EK. Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia. Aliment Pharmacol Ther 2021;54:532-3. [PMID: 34331806 DOI: 10.1111/apt.16468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Biemans VBC, Straatmijer T, Hoentjen F, Pierik MJ. Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply. Aliment Pharmacol Ther 2021;54:534-5. [PMID: 34331810 DOI: 10.1111/apt.16505] [Reference Citation Analysis]
20 Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol 2021;14:17562848211032126. [PMID: 34377149 DOI: 10.1177/17562848211032126] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Li Y, Jia Y, Cui T, Zhang J. IL-6/STAT3 signaling pathway regulates the proliferation and damage of intestinal epithelial cells in patients with ulcerative colitis via H3K27ac. Exp Ther Med 2021;22:890. [PMID: 34194568 DOI: 10.3892/etm.2021.10322] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Mahmoud R, van Lieshout C, Frederix GWJ, Jharap B, Oldenburg B. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. J Crohns Colitis 2021;15:709-18. [PMID: 33125060 DOI: 10.1093/ecco-jcc/jjaa219] [Reference Citation Analysis]
23 Arzi RS, Kay A, Raychman Y, Sosnik A. Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing. Pharmaceutics 2021;13:529. [PMID: 33920184 DOI: 10.3390/pharmaceutics13040529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2021:izab011. [PMID: 33586766 DOI: 10.1093/ibd/izab011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
26 Jodeleit H, Winkelmann P, Caesar J, Sterz S, Holdt LM, Beigel F, Stallhofer J, Breiteneicher S, Bartnik E, Leeuw T, Siebeck M, Gropp R. Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells. Dis Model Mech 2021;14:dmm046995. [PMID: 33293281 DOI: 10.1242/dmm.046995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Dwadasi S, Zafer M, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis 2020:izaa326. [PMID: 33319248 DOI: 10.1093/ibd/izaa326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hoffmann P, Globig AM, Thomann AK, Grigorian M, Krisam J, Hasselblatt P, Reindl W, Gauss A. Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study. J Clin Med 2020;9:E2177. [PMID: 32664204 DOI: 10.3390/jcm9072177] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
29 Biemans VB, Verstockt B. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease? United European Gastroenterol J 2020;8:753-4. [PMID: 32640933 DOI: 10.1177/2050640620942641] [Reference Citation Analysis]
30 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51:880-8. [PMID: 32237087 DOI: 10.1111/apt.15689] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]